Home Featured Page 16

Featured

Latest

Psychedelic Funding Update: Q3 2025

Megan Portnoy MS – Ontological Design, Psychedelic Spaces, and Integrating Rigor

The Psychedelic News Feed: October 6 – 12, 2025

Recovered or Reimagined? Samuli Kangaslampi on Psychedelics and Autobiographical Recall

Psychedelic Futures – Nowak Society featuring Joe Moore

Vince Kadlubek – Meow Wolf & PORTAL

The Tide Is Turning: Psychedelic Therapies Take a Step Toward the...

Behind the Bill: Inside a Bipartisan Effort to Bring Psychedelic Therapy...

Transcend Posts Positive Phase 2 Data from Methylone for PTSD Program

Pα+ Psychedelic Bulletin #192: Psychedelic Safety; Compass’ Lacklustre Long-Term Data; LSD...

February 2025 Psychedelic Patent Update: Terran Secures New Overlapping IP; Porta...

Beyond Guinea Pigs: Ensuring Access to Psychedelic Therapies for Europeans

SoundMind Institute – Dr Hannah McLane

Psychedelic Funding Update: Q3 2025

Megan Portnoy MS – Ontological Design, Psychedelic Spaces, and Integrating Rigor

The Psychedelic News Feed: October 6 – 12, 2025

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Psychedelic Funding Update: Q3 2025

Megan Portnoy MS – Ontological Design, Psychedelic Spaces, and Integrating Rigor

The Psychedelic News Feed: October 6 – 12, 2025

Recovered or Reimagined? Samuli Kangaslampi on Psychedelics and Autobiographical Recall

Psychedelic Futures – Nowak Society featuring Joe Moore

Vince Kadlubek – Meow Wolf & PORTAL

The Tide Is Turning: Psychedelic Therapies Take a Step Toward the...

Behind the Bill: Inside a Bipartisan Effort to Bring Psychedelic Therapy...

Fayzan Rab – Emory University

Transcend Posts Positive Phase 2 Data from Methylone for PTSD Program

Pα+ Psychedelic Bulletin #192: Psychedelic Safety; Compass’ Lacklustre Long-Term Data; LSD...

February 2025 Psychedelic Patent Update: Terran Secures New Overlapping IP; Porta...

Beyond Guinea Pigs: Ensuring Access to Psychedelic Therapies for Europeans

SoundMind Institute – Dr Hannah McLane

Natural Medicine Alaska

EDITOR PICKS

Psychedelic Funding Update: Q3 2025

Megan Portnoy MS – Ontological Design, Psychedelic Spaces, and Integrating Rigor

The Psychedelic News Feed: October 6 – 12, 2025

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY